News
-
-
-
PRESS RELEASE
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
Valneva reports positive final phase 2 antibody persistence and safety results for children with its Chikungunya vaccine IXCHIQ®. Twelve-month data supports full dose selection for Phase 3 trial -
-
-
-
-
-
-
PRESS RELEASE
SMX Moves Past Proof and Into the NAFRA Room Where Implementation Begins
SMX confirmed as featured presenter at NAFRA and American Chemistry Council program showcasing advanced plastic identification technology and capabilities. Strategic engagement to discuss operational rollout and industry adoption pathways